Literature DB >> 641153

Dominant inheritance of large molecular weight immunoreactive glucagon.

J P Palmer, P L Werner, J W Benson, J W Ensinck.   

Abstract

Plasma from some individuals contains substances which are reactive with glucagon antiserum, are larger than 3,500-dalton glucagon, and have been proposed as possible precursors of glucagon. We have evaluated three generations of a kindred in which 9 of 15 members evaluated had elevated plasma levels of large molecular weight immunoreactive glucagon (L-IRG) with an average concentration of 822 pg/ml. The distribution of individuals with elevated L-IRG levels in this pedigree is consistent with autosomal dominant inheritance. Gel filtration of plasma revealed that all affected family members had excessive amounts of two L-IRG peaks, one with a molecular weight of approximately 9,000 daltons and another in the 10,000 to 20,000-dalton range. Oral glucose tolerance tests were nondiabetic and elicited a fall in L-IRG levels, whereas L-IRG concentrations rose dramatically during the infusion of arginine. These L-IRG species may be precursors of 3,500-DALTON GLUCAGON AND MAY BE ELEVATED in this kindred because of an inherited defect in either their synthesis or degradation.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 641153      PMCID: PMC372591          DOI: 10.1172/JCI108990

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  28 in total

1.  High molecular weight glucagon-like immunoreactivity in plasma.

Authors:  G C Weir; S D Knowlton; D B Martin
Journal:  J Clin Endocrinol Metab       Date:  1975-02       Impact factor: 5.958

2.  The purification and biological properties of pancreatic big glucagon.

Authors:  K J O'Connor; N R Lazarus
Journal:  Biochem J       Date:  1976-05-15       Impact factor: 3.857

3.  Heterogeneity of plasma glucagon. Circulating components in normal subjects and patients with chronic renal failure.

Authors:  S F Kuku; J B Jaspan; D S Emmanouel; A Zeidler; A I Katz; A H Rubenstein
Journal:  J Clin Invest       Date:  1976-09       Impact factor: 14.808

4.  Presence of glucagon immunoreactivity in the globulin fraction of human plasma ("big plasma glucagon").

Authors:  I Valverde; M L Villanueva; I Lozano; J Marco
Journal:  J Clin Endocrinol Metab       Date:  1974-12       Impact factor: 5.958

5.  Complexity of immunoreactive forms of peptide hormones in plasma and in tissue extracts.

Authors:  R S Yalow
Journal:  Isr J Med Sci       Date:  1974-10

6.  A glucagonoma syndrome.

Authors:  C N Mallinson; S R Bloom; A P Warin; P R Salmon; B Cox
Journal:  Lancet       Date:  1974-07-06       Impact factor: 79.321

7.  A glucagon-secreting alpha-cell carcinoma of the pancreas.

Authors:  M H McGavran; R H Unger; L Recant; H C Polk; C Kilo; M E Levin
Journal:  N Engl J Med       Date:  1966-06-23       Impact factor: 91.245

8.  The effect of adrenergic blockade on the glucagon responses to starvation and hypoglycemia in man.

Authors:  R M Walter; R J Dudl; J P Palmer; J W Ensinck
Journal:  J Clin Invest       Date:  1974-11       Impact factor: 14.808

9.  Familial hyperglucagonemia--an autosomal dominant disorder.

Authors:  G Boden; O E Owen
Journal:  N Engl J Med       Date:  1977-03-10       Impact factor: 91.245

10.  Metabolism of endogenous proinsulin and insulin in man.

Authors:  J I Starr; A H Rubenstein
Journal:  J Clin Endocrinol Metab       Date:  1974-02       Impact factor: 5.958

View more
  1 in total

1.  Molecular heterogeneity of glucagon in normal subjects and in patients with glucagon-producing tumours.

Authors:  J J Holst
Journal:  Diabetologia       Date:  1983-05       Impact factor: 10.122

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.